

Google Cloud Services for Collecting, Processing, Analyzing, and Visualizing the Types of COVID-19 Vaccines

Ramamurthy Valavandan^{*}, Subhendu Ghosh, Kumaraswamy Reddy, Prasanth Parayatham, Ubaiyadulla Sherif, Vikram Sharma, Pragathi Sri, Vijayachandran Ramachandran, Surasa Mukherjee, Nitin Ambekar, Dinesh Sai Teja Neeli, Vijender Singh, Santosh Baran, Praveen Brian, Hanumantha Raj, Musheer Ahmed, Saurabh Uniyal

Kyndryl Solutions Private Limited, Google Cloud Guild, Nature Labs Project, Bangalore, India

Email address:

Ramamurthy.Valavandan@kyndryl.com (R. Valavandan), subhendu.Ghosh@kyndryl.com (S. Ghosh), Kumaraswamy.Yanamala@kyndryl.com (K. Reddy), Prasanth.Parayatham@kyndryl.com (P. Parayatham), Ubaiyadulla.Sherif@kyndryl.com (U. Sherif), Vikram.Sharma1@kyndryl.com (V. Sharma), pragathi.s@kyndryl.com (P. Sri), vijay.r1@kyndryl.com (V. Ramachandran), surasa.mukherjee@kyndryl.com (S. Mukherjee), nitin.ambekar@kyndryl.com (N. Ambekar), dinesh.sai.teja.neeli@kyndryl.com (D. S. T. Neeli), vijender.singh@kyndryl.com (V. Singh), Santosh.Baran@kyndryl.com (S. Baran), praveen.b@kyndryl.com (P. Brian), Hanumantha.R@kyndryl.com (H. Raj), Musheer.Ahmed.N@kyndryl.com (M. Ahmed), Saurabh.Uniyal@kyndryl.com (S. Uniyal)

^{*}Corresponding author

To cite this article:

Ramamurthy Valavandan, Subhendu Ghosh, Kumaraswamy Reddy, Prasanth Parayatham, Ubaiyadulla Sherif, Vikram Sharma, Pragathi Sri, Vijayachandran Ramachandran, Surasa Mukherjee, Nitin Ambekar, Dinesh Sai Teja Neeli, Vijender Singh, Santosh Baran, Praveen Brian, Hanumantha Raj, Musheer Ahmed, Saurabh Uniyal. Google Cloud Services for Collecting, Processing, Analyzing, and Visualizing the Types of COVID-19 Vaccines. *International Journal of Data Science and Analysis*. Vol. 8, No. 4, 2022, pp. 94-118.
doi: 10.11648/ijdsa.20220804.11

Received: June 16, 2022; **Accepted:** July 11, 2022; **Published:** July 28, 2022

Abstract: This study analyzes the types of COVID-19 vaccines used in different countries in Google Cloud native services. Big Query, a Google Cloud data analytics product, is used for data analytics. The python application is developed for data visualization of types of COVID-19 vaccines, and the application deployed in Google Cloud handles the data collection methodology. Google Cloud composer establishes the connection to the World Health Organization portal. Apache Airflow directed acyclic graph (DAG) runs in a Cloud Composer environment and Google Data Studio for data visualization. Google Guild members fully support the Google cloud Nature Labs projects. The motivation behind this project is our recent work on creating the ecosystem in Google Cloud for customers. The discovery, identification of Google service, the workload migration is designed for Google Cloud. The python application parses the types of vaccines of COVID-19 data in JSON format. The big query, a serverless data analytics of Google cloud, performs the classes of vaccines used in different countries. The python application parses the JSON file format and generates the report of the types the COVID-19 vaccines. Python application performs the data visualization in Google cloud, and Google data studio completes the functional requirement of reporting layer. The approach to studying the types of vaccines used in different countries is unique. As always, the data clenching task is a tedious task. Thanks to the research sponsor, SerpAPI provides the Google search results of variance of COVID-19 vaccines and chemical composition of vaccines of companies. The developed solution and the work products are highly reusable, and customers benefit from the outcome of this research assignment in the Google cloud innovation project of Nature Labs. The Google cloud native offers the dynamics for the scientific community on the study of types of vaccines for vaccine manufacturing companies. We conclude that out of thirty vaccine manufacturing companies, the World Health Organization (WHO) disapproves of Wuhan CNBG.

Keywords: COVID-19 Vaccine Types, Python Data Analytics, Google Compute Engine, Google SerpAPI, Google Cloud SQL, COVID-19 Vaccines Dataset, Analytics COVID-19 Vaccines, Google Cloud Big Query

1. Introduction

The motivation behind this research article is recent work on the Life-Saving Mission for COVID-19 Vaccination on Google Cloud (GC) Ecosystem [1] which was published in the International Journal of Science and Research. In this project, we gathered the types of COVID-19 [2] vaccine, and with the Google Cloud native services and the python application, the data visualization is achieved. This study aims to deal with COVID-19; various countries have made many efforts, including the research and development of vaccines. The purpose of this manuscript was to summarize the product, application, and problems of COVID-19 vaccines [3].

The methods adopted to review the existing literature to see the development of the COVID-19 vaccine [4].

The project scope is the analysis of COVID-19 vaccine types by provisioning the analytical [5] engine in Google Cloud for research and development in the healthcare sector.

The stakeholder of this research work is the research operation of Nature Labs (United Nations CSO) [6]. The project is open source for the healthcare domain [7]. The project is a tax exception and a noncommercial research program.

The project is managed by Google Cloud Guild members of Kyndryl Solutions Private Limited. The research requirement is the data visualization of COVID-19 [8-10] vaccination types in the Big Query of Google Cloud [11-18]. All the efforts, Google Cloud resources, services, and billing help the healthcare research, medical practitioners, government, and private body to access the Google data for the scope for decision making in the healthcare domain.

We address the correlation between the vaccine types and the country-specific development of manufacturing companies during the most challenging time while the world is battling COVID-19.

Google Cloud-native service of Big Query brings the usefulness of analysis of vaccine types and further research on vaccines.

2. Google Cloud for Data Analytics

Big Query is developed in Google Cloud for selecting the country and vaccine types for the data analytics. The service

is available 24X7X365 in the Google cloud.

```
SELECT country,
  regexp_replace (VACCINES_USED, ' ','\n') as
VACCINES_USED,
FROM
`tracing-matrix.COVID-19.WHO_Vaccination data`
WHERE
DATE(_PARTITIONTIME) = "2022-07-12"
GROUP BY 1,2
ORDER BY 1
```

3. Python for Parsing JSON of Vaccine

3.1. Use Case

We are creating the vaccination list of COVID-19 and visualization of JSON.

Program: parseserpapijsonvaccination.py

Created for Lab purposes with regulations of Nature Labs.

3.2. JSON Parser in Python

This program is an extension of generating the JSON file based on the WHO – Vaccination.

Google Search Engine API – SerpAPI.

Google Search Key: COVID-19 Vaccination types

JSON file input: vaccination.json

This program is used to parse JSON file, which is generated by Google Search API (SerpAPI).

JSON file has the information of the Google Search Engine.

Create the necessary folders, download, and save JSON for parsing vaccine types in search keys.

Two CSV files will be generated from Google Search Engine JSON [19].

1) vaccination.json

2) C:\google\serpapi\indias\data\Medicine

3.3. Serp API for Google Search

The functionality of the python application is to establish the Google Search Engine and Serp API, to generate the search results of Google in JSON file format. And create the necessary folders, load, and save JSON for parsing the search key results based on types of COVID-19 vaccine.




Figure 1. Big Query Vaccination dataset.




Figure 2. The caption of the GCP Console.

BigQuery Custom SQL




Figure 3. Big Query of Country-wise vaccination.




Figure 4. Big Query of Types of vaccination.




Figure 5. Big Query of Types of vaccination.




Figure 6. Big Query of Types of vaccination.




Figure 7. Google Data studio – number of types of vaccine.




Figure 8. Google Data Studio.

3.4. Table (Schema and Data Integration)

```
CREATE EXTERNAL TABLE `tracing-matrix.COVID-19.WHO_Vaccination_data`making
(
  COUNTRY STRING,
  ISO3 STRING,
  WHO_REGION STRING,
  DATA_SOURCE STRING,
```

```

DATE_UPDATED DATE,
TOTAL_VACCINATIONS FLOAT64,
PERSONS_VACCINATED_1PLUS_DOSE FLOAT64,
TOTAL_VACCINATIONS_PER100 FLOAT64,
PERSONS_VACCINATED_1PLUS_DOSE_PER100 FLOAT64,
PERSONS_FULLY_VACCINATED FLOAT64,
PERSONS_FULLY_VACCINATED_PER100 FLOAT64,
VACCINES_USED STRING,
FIRST_VACCINE_DATE DATE,
NUMBER_VACCINES_TYPES_USED FLOAT64,
PERSONS_BOOSTER_ADD_DOSE FLOAT64, PERSONS_BOOSTER_ADD_DOSE_PER100 FLOAT64
)
OPTIONS(
skip_leading_rows=0,
format="CSV",
uris=["https://drive.google.com/file/d/132PDmI2o9gParYa4F23o_IqdR8Ncxo0J/view?usp=sharing"]
);

```




Figure 9. Big Query Vaccination Project ID.




Figure 10. Vaccination list.

We have filtered the companies and types of vaccination available. Out of thirty vaccine manufacturing companies, the World Health Organization disapproves of Wuhan CNBG [20].

Table 1. Vaccination Companies and types of COVID-19 vaccine.

| | Companies | Vaccinations |
|----|-----------------|-----------------|
| 0 | Anhui ZL | Zifivax |
| 1 | AstraZeneca | AZD1222 |
| 2 | AstraZeneca | Vaxzevria |
| 3 | Beijing CNBG | BBIBP |
| 4 | Bharat | Covaxin |
| 5 | Biological E | Corbevax |
| 6 | CIGB | CIGB |
| 7 | CanSino | Convidecia |
| 8 | Chumakov | Covi |
| 9 | Finlay | Soberana Plus |
| 10 | Finlay | Soberana |
| 11 | Gamaleya | Gam |
| 12 | Gamaleya | Sputnik V |
| 13 | Gamaleya | Sputnik |
| 14 | IMB | COVIDful |
| 15 | Janssen | Ad26.COV 2 |
| 16 | Julphar | Hayat |
| 17 | Moderna | Spikevax |
| 18 | Moderna | mRNA |
| 19 | Novavax | NUVAXOVID |
| 20 | Pfizer BioNTech | Comirnaty |
| 21 | RIBSP | QazVac |
| 22 | SII | Covishield |
| 23 | SII | Covovax |
| 24 | SRCVB | EpiVacCorona |
| 25 | Shenzhen | LV |
| 26 | Shifa | COVIran Barakat |
| 27 | Sinovac | CoronaVac |
| 28 | Turkovac | ERUCOV-VAC |
| 29 | Wuhan CNBG | Inactivated |
| 30 | Zydus | ZyCov |

4. Google Cloud Analysis of Types of COVID-19 Vaccine

Our study on COVID-19 types of vaccines has provided an analytical view of every country and location. Google Analytics includes information on a complete picture of the vaccination dataset [21]. COVID-19 types of the vaccine are tabulated for India.

Bharat - Covaxin,
 Biological E - Corbevax,
 Gamaleya - Gam-COVID-Vac,
 Janssen - Ad26.COV 2-S,
 Moderna - Spikevax,
 SII - Covishield, SII - Covovax,
 Zydus - ZyCov-D

Table 2. Vaccination records.

| COUNTRY | TOTAL_VACCINATIONS | PERSONS_VACCINATED_1PLUS_DOSE |
|---------|--------------------|-------------------------------|
| India | 1906551885 | 1004921253 |

Nature Labs (Body of United Nations) research wing in COVID-19 and Google Cloud Guild members of Kyndryl Solutions Private Limited are contributors to application development in python, solutions and architecting for Cloud

adaptation, Google Cloud services of Big Query, and Compute Engine [22].

GCP Services and Resources

From a regulation perspective, the project has adhered to

healthcare standards [23] for meeting Blockchain and Privacy Computing compliance.

Google Cloud native-service, Big query, is handled by Kyndryl Solutions Private Limited to analyze types of

COVID-19 vaccines [24]. All the authors are pleased to support the publishers and any further communication from the readers and stakeholders [25].

Table 3. Google Cloud Services.

| GCP Service | GCP References |
|---|--|
| Compute Engine | a. https://cloud.google.com/compute b. particular Managed Instance Groups for scaling https://cloud.google.com/compute/docs/instance-groups#managed_instance_groups |
| Infrastructure as Code: use tools like Terraform to create multiple environments: | https://cloud.google.com/docs/terraform |
| Cloud CDN can provide Content Delivery Network services | https://cloud.google.com/cdn |
| Google Workspace can provide email services and plenty more when it comes to employee collaboration | https://workspace.google.com/ |
| MariaDB SkySQL runs on Google Cloud | a. https://mariadb.com/products/skysql/google-cloud-platform/ b. Or you can have Microsoft SQL Server, MySQL, and PostgreSQL as a service through the Cloud SQL service: https://cloud.google.com/sql |
| For high volume, high-performance storage for assets, nothing better than Google Cloud Storage | https://cloud.google.com/storage |
| And for shared NFS storage for web servers, check out Filestore | https://cloud.google.com/filestore |
| One can reserve public static IP addresses for web applications - be it a VM or a load balancer | https://cloud.google.com/compute/docs/ip-addresses/reserve-static-external-ip-address |
| Backup and Disaster Recovery tooling available | https://cloud.google.com/solutions/backup-dr |
| A broad range of SLAs are available and depending on solution architecture | a. https://cloud.google.com/terms/sla there is also comprehensive support offering depending on need b. https://cloud.google.com/support |

```

SELECT
COUNTRY,
DATE_UPDATED,
SAFE_CAST (TOTAL_VACCINATIONS AS INT64) AS TOTAL_VACCINATIONS,
SAFE_CAST (PERSONS_VACCINATED_1PLUS_DOSE AS INT64) AS PERSONS_VACCINATED_1PLUS_DOSE,
SAFE_CAST (PERSONS_FULLY_VACCINATED AS INT64) AS PERSONS_FULLY_VACCINATED,
regexp_replace (VACCINES_USED, r',', '\n') as VACCINES_USED,
FIRST_VACCINE_DATE,
SAFE_CAST (NUMBER_VACCINES_TYPES_USED AS INT64) AS NUMBER_VACCINES_TYPES_USED,
SAFE_CAST (PERSONS_BOOSTER_ADD_DOSE AS INT64) AS PERSONS_BOOSTER_ADD_DOSE
FROM
`tracing-matrix.COVID-19.WHO_Vaccination data`
WHERE
DATE(_PARTITIONTIME) = "2022-07-12"
GROUP BY 1,2,3,4,5,6,7,8,9
ORDER BY 1 DESC

```


















Figure 11. WHO Vaccination data.

← → ↻ <https://console.cloud.google.com/bigquery?referrer=search&project=tracing-matrix&ws=!1m0>              

Create table

Source

Create table from
Google Cloud Storage

Select file from GCS bucket or [use a URI pattern](#) *

☒ who_vaccination/vaccination-data.csv BROWSE

File format
CSV

☐ Source Data Partitioning

Destination

Project *
tracing-matrix BROWSE

Dataset *
covid19

Table *

CREATE TABLE CANCEL

Figure 12. Creating the Big Query Table.

COUNTRY
ISO3
WHO_REGION
DATA_SOURCE
DATE_UPDATED
TOTAL_VACCINATIONS
PERSONS_VACCINATED_1PLUS_DOSE
TOTAL_VACCINATIONS_PER100
PERSONS_VACCINATED_1PLUS_DOSE_PER100
PERSONS_FULLY_VACCINATED
PERSONS_FULLY_VACCINATED_PER100
VACCINES_USED
FIRST_VACCINE_DATE
NUMBER_VACCINES_TYPES_USED
PERSONS_BOOSTER_ADD_DOSE
PERSONS_BOOSTER_ADD_DOSE_PER100




Figure 13. Countries & Vaccine Types.




Figure 14. Google Bucket Creation.




Figure 15. Google Vaccination data uploading.




Figure 16. Google Big Query Schema.




Figure 17. Google Table partition.




Figure 18. Big Query Result.

5. Discussion

COVID-19 [26] Vaccine types used in different countries are processed in the Google Cloud. The Python program is developed for JSON parser [27], and 30 unique vaccine types are collected in Big Query [28]. Also, this project gives researchers an insight into vaccine types and the correlation between country and region [29].

6. Results

We found that different types [30] of vaccines had advantages and disadvantages. At the same time, the vaccine's side effects, the dose of vaccination, the efficacy evaluation, and its application [31] were worth studying.

7. Conclusion

The types of vaccines for COVID-19 [32-38] are used in different countries, and the chemical composition is brought into Google Cloud for further progress in the research on vaccines. The contribution of vaccine companies is essential for further developing the immunogenicity and reactivity of the vaccines. We hope this review can help colleagues across the world.

Google Cloud Guild Team [38] has contributed data analytics and provisioning of Google Cloud to study COVID-19 vaccine types.

Google Cloud Engine [39] is also worked for research for Nature Labs in measuring the chemical components [40] of the COVID-19 vaccine. The project brings a message to the vaccine manufacturing companies on the need for Google Cloud for data analysis, chemical, and research-related work in Google cloud-native services of Big Query, and

application modernization, Google Kubernetes Engine (GKE) for Virtual Machine (VMs), the discovery, analysis of machine data of source information of datacenter for creating the working template for process of migration in Google, Application as a service in python and big query in segregation. The available information is handy for data analytics in the Python application interface in SerpAPI application modernization in Google Cloud. In this data analytics, the vaccine manufacturing companies can bring their workload to Google Cloud, and the Nature Labs research analytics engine solves the necessary healthcare-related projects for the vaccine manufacturing companies. The certification in Google Cloud helps the manufacturing companies gain consumer confidence.

Breakdown of the three COVID vaccines and their ingredients:

- (1) Pfizer Vaccine:
mRNA, lipids ((4-hydroxybutyl) azanediyl)bis (hexane-6,1-diyl)bis(2-hexyldecanoate), 2 [[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 1,2-Distearoyl-sn-glycero-3-phosphocholine, and cholesterol), potassium chloride, monobasic potassium phosphate, sodium chloride, dibasic sodium phosphate dihydrate, and sucrose.
- (2) Moderna Vaccine:
Messenger ribonucleic acid (mRNA), lipids (SM-102, polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG], cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]), tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate trihydrate, and sucrose.
- (3) Johnson & Johnson Vaccine:
Recombinant, replication-incompetent adenovirus type 26 expressing the SARS-CoV-2 spike protein, citric acid monohydrate, trisodium citrate dihydrate, ethanol, 2 hydroxypropyl- β -cyclodextrin (HBCD), polysorbate-80, sodium chloride.

Authors' Contributions

Kyndryl Solutions Private Limited, GCP Guild members, have contributed their time and efforts for the WHO successfully in provisioning the dataset and automated Python programing, Big Query Tables.

Google Search Engine @ Google Cloud by SerpAPI

Date: July 09, 2022

Google Connect is a utility to connect to the Google Search Engine.

Motivation: To Google Cloud Search Application Program Interface (API) to connect to Google Search Engine and select the exact URL in Google Cloud Engine, which is connected via SerpAPI in Python.

Cloud Service used: Google Compute Engine, Google Storage, Cloud Composer, Google Kubernetes Engine.

SerpAPI Sponsorship

SerpAPI sponsors Google Engine @ Nature Labs. SerpAPI is the Key factor for our success in scraping the Google search engine.

On behalf of Nature Labs researchers, we express our gratitude to SerpAPI LLC for provisioning their sponsorship SerpAPI's sponsorship has helped us make our research and social work contribution to speaking out greater audience.

With the advent of SerpAPI, Nature Labs has addressed our research work on Temples in India with the experience of a blazingly fast, super easy to use, and data-rich API in Google Cloud Platform Search Engine on Big Query for Research in Google Cloud Engine. With SerpAPI, Nature Labs will be helping the community projects.

About SerpApi

SERP API is a real-time API to access Google search results. It solves the issues of having to rent proxies, solving captchas, and JSON parsing.

SerpApi

Purpose: Google Connect is a utility to connect to the Google Search Engine.

Generate the CSV data based on the search query given in the argument.

The demonstrated program generates the datasheet in a format CSV.

Design and developed by:

Project Team: Google Cloud Platform - Guild.

Lab: Nature Labs @ GCP

<https://github.com/gcpguild/googlengine/blob/main/parseserpapijsonvaccination.py>

Types of COVID-19 vaccine study reveal the bulk of the vaccine manufacturing formula is needed to be qualified in Google Cloud data analysis and Chemical analysis of Nature Labs. Chemical analysis is recommended for the confidence factors of the consumers. Also, the data for countries like Bonaire, Eritrea, Saba, and Sint Eustatius is unavailable. Vaccination against COVID-19 in St. Eustatius started in February 2021. In 2021, the Moderna Vaccine was used. Since January 2022, the Pfizer Vaccine booster vaccinations and booster vaccinations.

Table 4. Big Query for Vaccination Data.

| S. No | Companies | Vaccinations | |
|-------|-------------|--------------|--|
| 0 | Anhui ZL | Zifivax | ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom |
| 1 | AstraZeneca | AZD1222 | The Oxford–AstraZeneca COVID-19 vaccine, codenamed AZD1222, sold under the brand names Covishield and Vaxzevria, among others, is a viral vector vaccine for the prevention of COVID-19. Vaxzevria is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 18 years and older. The SARS-CoV-2 virus causes COVID-19s. Vaxzevria is made up of another virus (of the adenovirus family) modified to contain the gene for making a protein from SARS-CoV-2. |
| 2 | AstraZeneca | Vaxzevria | |

| S. No | Companies | Vaccinations | |
|-------|-----------------|-----------------|--|
| 3 | Beijing CNBG | BBIBP | The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, the Sinopharm COVID-19 vaccine, or BIBP vaccine, is one of two whole inactivated virus COVID-19 vaccines developed by Sinopharm's Beijing Institute of Biological Products. |
| 4 | Bharat | Covaxin | the Technical Advisory Group for Emergency Use Listing listed the Bharat Biotech BBV152 COVAXIN vaccine against COVID-19 for emergency use. The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has issued interim policy recommendations for using the Bharat Biotech BBV152 COVAXIN vaccine. This article provides a summary of those interim recommendations. |
| 5 | Biological E | Corbevax | Biological E. Limited CorbeVax® COVID-19 Vaccine (BioE COVID-19, BECOV2D) is based on classical a protein subunit vaccine technology of a protein antigen, SARS-CoV-2 Spike receptor-binding domain (RBD), adsorbed to the adjuvant Alhydrogel (Alum), in combination with another approved adjuvant, |
| 6 | CIGB | CIGB | |
| 7 | CanSino | Convidecia | CanSinoBio Biologics Inc. Convidecia™ (Ad5-nCoV) is a novel recombinant viral vector vaccine for COVID-19 produced in China. The single-dose vaccine was developed on CanSinoBio's adenovirus-based viral vector vaccine technology platform and the Beijing Institute of Biotechnology. |
| 8 | Chumakov | Covi | Russia's Chumakov research center officially launched the production of the nation's third coronavirus vaccine, CoviVac, in late March. CoviVac is a so-called whole-virion vaccine based on a modified SARS-CoV-2 virus that can not cause the disease but boosts immunity against coronavirus. |
| 9 | Finlay | Soberana Plus | Soberana Plus Soberana Plus, technical name FINLAY-FR-1A, is a COVID-19 candidate vaccine produced by the Finlay Institute, a Cuban epidemiological research institute. |
| 10 | Finlay | Soberana | Soberana 02 or Soberana 2, technical name FINLAY-FR-2, is a COVID-19 vaccine produced by the Finlay Institute, a Cuban epidemiological research institute. The vaccine is known as PastoC.ovac. |
| 11 | Gamaleya | Gam | Gamaleya: Gam-COVID-Vac. Vaccine Type: Non-Replicating Viral Vector This vaccine may also be referred to as Sputnik, rAd5. Vaccine Trial & Approval Tracker. Phase 1; Phase 2; Phase 3 |
| 12 | Gamaleya | Sputnik V | sputnik v demonstrates 97% efficacy against hospitalization caused by omicron variant following revaccination with sputnik light or sputnik v, according to a study published in the vaccines peer-reviewed leading medical journal. |
| 13 | Gamaleya | Sputnik | Sputnik V (Russian: Спутник V, the brand name from RDIF) or Gam-COVID-Vac (Russian: Гам-КОВИД-Вак, the name under which it is legally registered and produced [3]) is an adenovirus viral vector vaccine for COVID-19 developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Russia. It is the world's first registered combination vector vaccine for the prevention of COVID-19, registered on 11 August 2020 by the Russian Ministry of Health. |
| 14 | IMB | COVIDful | |
| 15 | Janssen | Ad26.COV 2 | The Janssen COVID-19 vaccine is sold under the brand name Jcovden. |
| 16 | Julphar | Hayat | |
| 17 | Moderna | Spikevax | The vaccine has been known as the Moderna COVID-19 Vaccine and will now be marketed as Spikevax, for the prevention of COVID-19 in individuals 18 years of age and older. Moderna COVID-19 Vaccine |
| 18 | Moderna | mRNA | The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has issued updated interim recommendations for the Moderna COVID-19 (mRNA-1273) vaccine against COVID-19. |
| 19 | Novavax | NUVAXOVID | NVX-CoV2373 (Novavax COVID-19 vaccine) In January 2020, Novavax announced the development of a vaccine candidate, NVX-CoV2373, to establish immunity to SARS-CoV-2. NVX-CoV2373 is a protein subunit vaccine that contains the spike protein of the SARS-CoV-2 molecule |
| 20 | Pfizer BioNTech | Comirnaty | The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with American company Pfizer to carry out clinical trials, logistics, and manufacturing. It is authorized for use in people aged five years and older in some jurisdictions, twelve years and older in some jurisdictions, and for people sixteen years and older in other jurisdictions to protect against COVID-19, caused by infection with the SARS-CoV-2 virus. |
| 21 | RIBSP | QazVac | Research Institute for Biological Safety Problems (RIBSP): QazVac. Vaccine Type: Inactivated. This vaccine may also be referred to as QazCOVID-in. Vaccine Trial & Approval Tracker. Phase 1; Phase 2; Phase 3; Approved; This vaccine is approved. |
| 22 | SII | Covishield | CoviShield is the Serum Institute of India version of the AstraZeneca COVID-19 vaccine. On February 15, 2021, the World Health Organization (WHO) recommended the Serum Institute of India (SII) COVID-19 Vaccine (ChAdOx1-S [recombinant]), known as COVISHIELD. |
| 23 | SII | Covovax | This is SII's version of NVX-CoV2373, the protein-based COVID-19 vaccine developed by Novavax, headquartered in the USA. In August 2020, the two companies announced an agreement under which Novavax had given SII the license to manufacture and supply the vaccine in low- and middle-income countries and India. |
| 24 | SRCVB | EpiVacCorona | EpiVacCorona (Russian: ЭпиВакКорона, tr. EpiVakKorona) is a peptide-based vaccine against COVID-19 developed by the VECTOR center of Virology. It consists of three chemically synthesized peptides (short fragments of a viral spike protein) conjugated to a large carrier protein. |
| 25 | Shenzhen | LV | |
| 26 | Shifa | COVIran Barakat | COVIran Barekat (Persian) is a COVID-19 vaccine developed in Iran by Shifa Pharm Industrial Group, a subsidiary of the Barkat Pharmaceutical Group. It is an inactivated virus-based vaccine. |
| 27 | Sinovac | CoronaVac | CoronaVac, also known as the Sinovac COVID-19 vaccine, [3] is a whole inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. It was Phase III clinical trailed in Brazil, [6] Chile, Indonesia, the Philippines, and Turkey and relied on traditional technology similar to other inactivated-virus COVID-19 vaccines, |

| S. No | Companies | Vaccinations | |
|-------|------------|--------------|--|
| 28 | Turkovac | ERUCOV-VAC | Turkovac (temporarily named ERUCOV-VAC) is a COVID-19 vaccine developed by the Heathe lth Institutes of türkiye and Erciyes University. Clinical trials |
| 29 | Wuhan CNBG | Inactivated | |
| 30 | Zyduş | ZyCov | ZyCov-D is a “plasmid DNA” vaccine — or a vaccine that uses a genetically engineered, non-replicating version of a type of DNA molecule known as a ‘plasmid.’ The plasmids, in this case, are coded with the instructions to make the spike protein of SARS-CoV-2, the coronavirus that causes COVID-19. |

Software download References:

<https://github.com/gcpguild/googlengine/blob/main/parseserpapijsonvaccination.py>

<https://github.com/gcpguild/googlengine/blob/main/vaccination.json>

<https://github.com/gcpguild/COVID-19>

Appendix

COVID-19 Vaccine Types

Afghanistan
AstraZeneca - Vaxzevria
Beijing CNBG - BBIBP-CorV
Bharat - Covaxin
CanSino - Convidecia
Gamaleya - Gam-COVID-Vac
Gamaleya - Sputnik-Light
Janssen - Ad26.COV 2-S
Moderna - Spikevax
Pfizer BioNTech - Comirnaty
SII - Covishield
Sinovac - CoronaVac
Albania
AstraZeneca - Vaxzevria
Gamaleya - Gam-COVID-Vac
Pfizer BioNTech - Comirnaty
SII - Covishield
Sinovac - CoronaVac
Algeria
Beijing CNBG - BBIBP-CorV
Gamaleya - Gam-COVID-Vac
SII - Covishield
Sinovac - CoronaVac
American Samoa
Janssen - Ad26.COV 2-S
Moderna - Spikevax
Pfizer BioNTech - Comirnaty
Andorra
AstraZeneca - Vaxzevria
Moderna - Spikevax
Pfizer BioNTech - Comirnaty
Angola
SII - Covishield
Anguilla
AstraZeneca - Vaxzevria
Pfizer BioNTech - Comirnaty
Antigua and Barbuda
AstraZeneca - Vaxzevria
Beijing CNBG - BBIBP-CorV
Gamaleya - Gam-COVID-Vac
Janssen - Ad26.COV 2-S
Pfizer BioNTech - Comirnaty
SII - Covishield
Argentina
AstraZeneca - Vaxzevria
Beijing CNBG - BBIBP-CorV
CanSino - Convidecia
Gamaleya - Gam-COVID-Vac
Moderna - Spikevax
Pfizer BioNTech - Comirnaty
SII - Covishield

COVID-19 Vaccine Types

Armenia
AstraZeneca - Vaxzevria
Beijing CNBG - BBIBP-CorV
Gamaleya - Gam-COVID-Vac
Gamaleya - Sputnik-Light
Moderna - Spikevax
Pfizer BioNTech - Comirnaty
Sinovac - CoronaVac
Wuhan CNBG - Inactivated
Aruba
Janssen - Ad26.COV 2-S
Pfizer BioNTech - Comirnaty
Australia
AstraZeneca - Vaxzevria
Janssen - Ad26.COV 2-S
Moderna - Spikevax
Novavax-NUVAXOVID
Pfizer BioNTech - Comirnaty
Austria
AstraZeneca - Vaxzevria
Janssen - Ad26.COV 2-S
Moderna - Spikevax
Novavax-NUVAXOVID
Pfizer BioNTech - Comirnaty
Unknown Vaccine
Azerbaijan
AstraZeneca - Vaxzevria
Gamaleya - Gam-COVID-Vac
Gamaleya - Sputnik-Light
Pfizer BioNTech - Comirnaty
Sinovac - CoronaVac
Bahamas
AstraZeneca - Vaxzevria
Janssen - Ad26.COV 2-S
Pfizer BioNTech - Comirnaty
SII - Covishield
Bahrain
AstraZeneca - Vaxzevria
Beijing CNBG - BBIBP-CorV
Bharat - Covaxin
CanSino - Convidecia
Gamaleya - Gam-COVID-Vac
Gamaleya - Sputnik-Light
Janssen - Ad26.COV 2-S
Moderna - Spikevax
Pfizer BioNTech - Comirnaty
SII - Covishield
Sinovac - CoronaVac
Bangladesh
AstraZeneca - Vaxzevria
Beijing CNBG - BBIBP-CorV
Gamaleya - Gam-COVID-Vac
Janssen - Ad26.COV 2-S
Moderna - Spikevax

| COVID-19 Vaccine Types | COVID-19 Vaccine Types |
|----------------------------------|------------------------------|
| Pfizer BioNTech - Comirnaty | Pfizer BioNTech - Comirnaty |
| SII - Covishield | SII - Covishield |
| Sinovac - CoronaVac | Sinovac - CoronaVac |
| Barbados | British Virgin Islands |
| AstraZeneca - Vaxzevria | AstraZeneca - Vaxzevria |
| Beijing CNBG - BBIBP-CorV | Janssen - Ad26.COV 2-S |
| Janssen - Ad26.COV 2-S | Brunei Darussalam |
| Pfizer BioNTech - Comirnaty | AstraZeneca - Vaxzevria |
| SII - Covishield | Beijing CNBG - BBIBP-CorV |
| Belarus | Janssen - Ad26.COV 2-S |
| Beijing CNBG - BBIBP-CorV | Moderna - Spikevax |
| Chumakov - Covi-Vac | Pfizer BioNTech - Comirnaty |
| Gamaleya - Gam-COVID-Vac | Bulgaria |
| Gamaleya - Sputnik-Light | AstraZeneca - Vaxzevria |
| Belgium | Janssen - Ad26.COV 2-S |
| AstraZeneca - Vaxzevria | Moderna - Spikevax |
| Janssen - Ad26.COV 2-S | Pfizer BioNTech - Comirnaty |
| Moderna - Spikevax | Burkina Faso |
| Pfizer BioNTech - Comirnaty | Beijing CNBG - BBIBP-CorV |
| Belize | Janssen - Ad26.COV 2-S |
| AstraZeneca - Vaxzevria | SII - Covishield |
| Beijing CNBG - BBIBP-CorV | Burundi |
| Janssen - Ad26.COV 2-S | Beijing CNBG - BBIBP-CorV |
| Pfizer BioNTech - Comirnaty | Cabo Verde |
| SII - Covishield | Beijing CNBG - BBIBP-CorV |
| Benin | Moderna - Spikevax |
| AstraZeneca - Vaxzevria | Pfizer BioNTech - Comirnaty |
| Janssen - Ad26.COV 2-S | SII - Covishield |
| Pfizer BioNTech - Comirnaty | Ivory Coast |
| SII - Covishield | Beijing CNBG - BBIBP-CorV |
| Sinovac - CoronaVac | Gamaleya - Gam-COVID-Vac |
| Bermuda | Janssen - Ad26.COV 2-S |
| AstraZeneca - Vaxzevria | Pfizer BioNTech - Comirnaty |
| Pfizer BioNTech - Comirnaty | SII - Covishield |
| Bhutan | Cambodia |
| AstraZeneca - Vaxzevria | AstraZeneca - Vaxzevria |
| Beijing CNBG - BBIBP-CorV | Beijing CNBG - BBIBP-CorV |
| Moderna - Spikevax | Janssen - Ad26.COV 2-S |
| Pfizer BioNTech - Comirnaty | Moderna - Spikevax |
| SII - Covishield | Pfizer BioNTech - Comirnaty |
| Bolivia (Plurinational State of) | SII - Covishield |
| Beijing CNBG - BBIBP-CorV | Sinovac - CoronaVac |
| Gamaleya - Gam-COVID-Vac | Cameroon |
| Janssen - Ad26.COV 2-S | Beijing CNBG - BBIBP-CorV |
| Moderna - Spikevax | Janssen - Ad26.COV 2-S |
| Pfizer BioNTech - Comirnaty | Pfizer BioNTech - Comirnaty |
| SII - Covishield | SII - Covishield |
| Bonaire | Canada |
| None | AstraZeneca - Vaxzevria |
| Bonaire, Sint Eustatius and Saba | Janssen - Ad26.COV 2-S |
| Moderna - Spikevax | Moderna - Spikevax |
| Pfizer BioNTech - Comirnaty | Pfizer BioNTech - Comirnaty |
| Bosnia and Herzegovina | SII - Covishield |
| AstraZeneca - AZD1222 | Cayman Islands |
| Pfizer BioNTech - Comirnaty | Pfizer BioNTech - Comirnaty |
| Sinovac - CoronaVac | The central African Republic |
| Gamaleya - Sputnik V | Bharat - Covaxin |
| Botswana | SII - Covishield |
| Bharat - Covaxin | Chad |
| Janssen - Ad26.COV 2-S | Beijing CNBG - BBIBP-CorV |
| Moderna - Spikevax | Chile |
| Pfizer BioNTech - Comirnaty | AstraZeneca - Vaxzevria |
| SII - Covishield | CanSino - Convidecia |
| Sinovac - CoronaVac | Moderna - Spikevax |
| Brazil | Pfizer BioNTech - Comirnaty |
| AstraZeneca - Vaxzevria | Sinovac - CoronaVac |
| Janssen - Ad26.COV 2-S | China |

| COVID-19 Vaccine Types | COVID-19 Vaccine Types |
|--------------------------------------|-----------------------------|
| Anhui ZL - Zifivax | Bharat - Covaxin |
| Beijing CNBG - BBIBP-CorV | CanSino - Convidecia |
| CanSino - Convidecia | Gamaleya - Gam-COVID-Vac |
| IMB - COVIDful | Gamaleya - Sputnik-Light |
| Pfizer BioNTech - Comirnaty | Janssen - Ad26.COV 2-S |
| Shenzhen - LV-SMENP-DC | Moderna - Spikevax |
| Sinovac - CoronaVac | Pfizer BioNTech - Comirnaty |
| Wuhan CNBG - Inactivated | SII - Covishield |
| Colombia | Sinovac - CoronaVac |
| AstraZeneca - Vaxzevria | Dominica |
| Janssen - Ad26.COV 2-S | AstraZeneca - Vaxzevria |
| Moderna - Spikevax | Beijing CNBG - BBIBP-CorV |
| Pfizer BioNTech - Comirnaty | Pfizer BioNTech - Comirnaty |
| Sinovac - CoronaVac | SII - Covishield |
| Comoros | Dominican Republic |
| Beijing CNBG - BBIBP-CorV | AstraZeneca - Vaxzevria |
| Bharat - Covaxin | SII - Covishield |
| SII - Covishield | Sinovac - CoronaVac |
| Congo | Ecuador |
| Beijing CNBG - BBIBP-CorV | AstraZeneca - Vaxzevria |
| Gamaleya - Gam-COVID-Vac | CanSino - Convidecia |
| Moderna - Spikevax | Pfizer BioNTech - Comirnaty |
| SII - Covishield | Sinovac - CoronaVac |
| Cook Islands | Egypt |
| Pfizer BioNTech - Comirnaty | AstraZeneca - Vaxzevria |
| Costa Rica | Beijing CNBG - BBIBP-CorV |
| AstraZeneca - Vaxzevria | Bharat - Covaxin |
| Moderna - Spikevax | CanSino - Convidecia |
| Pfizer BioNTech - Comirnaty | Gamaleya - Gam-COVID-Vac |
| Croatia | Gamaleya - Sputnik-Light |
| AstraZeneca - Vaxzevria | Janssen - Ad26.COV 2-S |
| Janssen - Ad26.COV 2-S | Moderna - Spikevax |
| Moderna - Spikevax | Pfizer BioNTech - Comirnaty |
| Novavax-NUVAXOVID | Sinovac - CoronaVac |
| Pfizer BioNTech - Comirnaty | El Salvador |
| Unknown Vaccine | AstraZeneca - Vaxzevria |
| Cuba | Beijing CNBG - BBIBP-CorV |
| CIGB - CIGB-66 | Moderna - Spikevax |
| Finlay - Soberana Plus | Pfizer BioNTech - Comirnaty |
| Finlay - Soberana-02 | SII - Covishield |
| Curaçao | Sinovac - CoronaVac |
| AstraZeneca - Vaxzevria | Equatorial Guinea |
| Moderna - Spikevax | Beijing CNBG - BBIBP-CorV |
| Pfizer BioNTech - Comirnaty | Sinovac - CoronaVac |
| Cyprus | Eritrea |
| AstraZeneca - Vaxzevria | None |
| Janssen - Ad26.COV 2-S | Estonia |
| Moderna - Spikevax | AstraZeneca - Vaxzevria |
| Novavax-NUVAXOVID | Janssen - Ad26.COV 2-S |
| Pfizer BioNTech - Comirnaty | Moderna - Spikevax |
| Czechia | Novavax-NUVAXOVID |
| AstraZeneca - Vaxzevria | Pfizer BioNTech - Comirnaty |
| Janssen - Ad26.COV 2-S | Eswatini |
| Moderna - Spikevax | Janssen - Ad26.COV 2-S |
| Novavax-NUVAXOVID | Pfizer BioNTech - Comirnaty |
| Pfizer BioNTech - Comirnaty | SII - Covishield |
| The Democratic Republic of the Congo | Ethiopia |
| SII - Covishield | Beijing CNBG - BBIBP-CorV |
| Denmark | Bharat - Covaxin |
| AstraZeneca - Vaxzevria | Janssen - Ad26.COV 2-S |
| Janssen - Ad26.COV 2-S | SII - Covishield |
| Moderna - Spikevax | Falkland Islands (Malvinas) |
| Pfizer BioNTech - Comirnaty | AstraZeneca - AZD1222 |
| Unknown Vaccine | Faroe Islands |
| Djibouti | Moderna - mRNA-1273 |
| AstraZeneca - Vaxzevria | Pfizer BioNTech - Comirnaty |
| Beijing CNBG - BBIBP-CorV | Fiji |

| COVID-19 Vaccine Types | COVID-19 Vaccine Types |
|-----------------------------|-----------------------------|
| AstraZeneca - Vaxzevria | Moderna - Spikevax |
| Moderna - Spikevax | Pfizer BioNTech - Comirnaty |
| SII - Covishield | Guatemala |
| Finland | AstraZeneca - Vaxzevria |
| AstraZeneca - Vaxzevria | Gamaleya - Gam-COVID-Vac |
| Janssen - Ad26.COV 2-S | Moderna - Spikevax |
| Moderna - Spikevax | Pfizer BioNTech - Comirnaty |
| Pfizer BioNTech - Comirnaty | SII - Covishield |
| Unknown Vaccine | Guernsey |
| France | Moderna - mRNA-1273 |
| AstraZeneca - Vaxzevria | AstraZeneca - AZD1222 |
| Janssen - Ad26.COV 2-S | Pfizer BioNTech - Comirnaty |
| Moderna - Spikevax | Guinea |
| Novavax-NUVAXOVID | Beijing CNBG - BBIBP-CorV |
| Pfizer BioNTech - Comirnaty | Gamaleya - Gam-COVID-Vac |
| Unknown Vaccine | Janssen - Ad26.COV 2-S |
| French Guiana | Pfizer BioNTech - Comirnaty |
| Moderna - Spikevax | SII - Covishield |
| Pfizer BioNTech - Comirnaty | Sinovac - CoronaVac |
| French Polynesia | Guinea-Bissau |
| Janssen - Ad26.COV 2-S | Beijing CNBG - BBIBP-CorV |
| Pfizer BioNTech - Comirnaty | SII - Covishield |
| Gabon | Guyana |
| Beijing CNBG - BBIBP-CorV | AstraZeneca - Vaxzevria |
| Gamaleya - Gam-COVID-Vac | Beijing CNBG - BBIBP-CorV |
| Pfizer BioNTech - Comirnaty | Gamaleya - Gam-COVID-Vac |
| The Gambia | Janssen - Ad26.COV 2-S |
| Beijing CNBG - BBIBP-CorV | Moderna - Spikevax |
| SII - Covishield | Pfizer BioNTech - Comirnaty |
| Georgia | SII - Covishield |
| AstraZeneca - Vaxzevria | Haiti |
| Beijing CNBG - BBIBP-CorV | Janssen - Ad26.COV 2-S |
| Pfizer BioNTech - Comirnaty | Moderna - Spikevax |
| Sinovac - CoronaVac | Honduras |
| Germany | AstraZeneca - Vaxzevria |
| AstraZeneca - Vaxzevria | Gamaleya - Gam-COVID-Vac |
| Janssen - Ad26.COV 2-S | Janssen - Ad26.COV 2-S |
| Moderna - Spikevax | Moderna - Spikevax |
| Novavax-NUVAXOVID | Pfizer BioNTech - Comirnaty |
| Pfizer BioNTech - Comirnaty | SII - Covishield |
| Unknown Vaccine | Hungary |
| Ghana | AstraZeneca - Vaxzevria |
| Gamaleya - Gam-COVID-Vac | Beijing CNBG - BBIBP-CorV |
| SII - Covishield | Gamaleya - Gam-COVID-Vac |
| Gibraltar | Janssen - Ad26.COV 2-S |
| AstraZeneca - AZD1222 | Moderna - Spikevax |
| Pfizer BioNTech - Comirnaty | Pfizer BioNTech - Comirnaty |
| Greece | Sinovac - CoronaVac |
| AstraZeneca - Vaxzevria | Iceland |
| Janssen - Ad26.COV 2-S | AstraZeneca - Vaxzevria |
| Moderna - Spikevax | Janssen - Ad26.COV 2-S |
| Novavax-NUVAXOVID | Moderna - Spikevax |
| Pfizer BioNTech - Comirnaty | Pfizer BioNTech - Comirnaty |
| Greenland | India |
| Moderna - mRNA-1273 | Bharat - Covaxin |
| Grenada | Biological E - Corbevax |
| AstraZeneca - Vaxzevria | Gamaleya - Gam-COVID-Vac |
| Janssen - Ad26.COV 2-S | Janssen - Ad26.COV 2-S |
| Pfizer BioNTech - Comirnaty | Moderna - Spikevax |
| SII - Covishield | SII - Covishield |
| Guadeloupe | SII - Covovax |
| AstraZeneca - Vaxzevria | Zydus - ZyCov-D |
| Janssen - Ad26.COV 2-S | Indonesia |
| Moderna - Spikevax | AstraZeneca - Vaxzevria |
| Pfizer BioNTech - Comirnaty | Beijing CNBG - BBIBP-CorV |
| Guam | Janssen - Ad26.COV 2-S |
| Janssen - Ad26.COV 2-S | Moderna - Spikevax |

| COVID-19 Vaccine Types | COVID-19 Vaccine Types |
|--------------------------------|----------------------------------|
| Novavax-NUVAXOVID | Gamaleya - Gam-COVID-Vac |
| Pfizer BioNTech - Comirnaty | Gamaleya - Sputnik-Light |
| Sinovac - CoronaVac | Janssen - Ad26.COV 2-S |
| Iran (the Islamic Republic of) | Moderna - Spikevax |
| AstraZeneca - Vaxzevria | Pfizer BioNTech - Comirnaty |
| Beijing CNBG - BBIBP-CorV | Sinovac - CoronaVac |
| Bharat - Covaxin | Kazakhstan |
| CanSino - Convidecia | Beijing CNBG - BBIBP-CorV |
| Finlay - Soberana-02 | Gamaleya - Gam-COVID-Vac |
| Gamaleya - Gam-COVID-Vac | Pfizer BioNTech - Comirnaty |
| Gamaleya - Sputnik-Light | RIBSP - QazVac |
| Janssen - Ad26.COV 2-S | Sinovac - CoronaVac |
| Moderna - Spikevax | Kenya |
| Pfizer BioNTech - Comirnaty | Beijing CNBG - BBIBP-CorV |
| Shifa - COVIran Barakat | Janssen - Ad26.COV 2-S |
| Sinovac - CoronaVac | Moderna - Spikevax |
| Iraq | Pfizer BioNTech - Comirnaty |
| AstraZeneca - Vaxzevria | SII - Covishield |
| Beijing CNBG - BBIBP-CorV | Kiribati |
| Bharat - Covaxin | AstraZeneca - Vaxzevria |
| CanSino - Convidecia | Beijing CNBG - BBIBP-CorV |
| Gamaleya - Gam-COVID-Vac | Kosovo |
| Gamaleya - Sputnik-Light | AstraZeneca - Vaxzevria |
| Janssen - Ad26.COV 2-S | Pfizer BioNTech - Comirnaty |
| Moderna - Spikevax | Kuwait |
| Pfizer BioNTech - Comirnaty | AstraZeneca - Vaxzevria |
| Sinovac - CoronaVac | Beijing CNBG - BBIBP-CorV |
| Ireland | Bharat - Covaxin |
| AstraZeneca - Vaxzevria | CanSino - Convidecia |
| Janssen - Ad26.COV 2-S | Gamaleya - Gam-COVID-Vac |
| Moderna - Spikevax | Gamaleya - Sputnik-Light |
| Novavax-NUVAXOVID | Janssen - Ad26.COV 2-S |
| Pfizer BioNTech - Comirnaty | Moderna - Spikevax |
| Isle of Man | Pfizer BioNTech - Comirnaty |
| Moderna - mRNA-1273 | Sinovac - CoronaVac |
| AstraZeneca - AZD1222 | Kyrgyzstan |
| Pfizer BioNTech - Comirnaty | AstraZeneca - Vaxzevria |
| Israel | Beijing CNBG - BBIBP-CorV |
| AstraZeneca - Vaxzevria | Gamaleya - Gam-COVID-Vac |
| Moderna - Spikevax | Moderna - Spikevax |
| Pfizer BioNTech - Comirnaty | Pfizer BioNTech - Comirnaty |
| Italy | RIBSP - QazVac |
| AstraZeneca - Vaxzevria | Lao People's Democratic Republic |
| Janssen - Ad26.COV 2-S | AstraZeneca - Vaxzevria |
| Moderna - Spikevax | Beijing CNBG - BBIBP-CorV |
| Novavax-NUVAXOVID | Gamaleya - Gam-COVID-Vac |
| Pfizer BioNTech - Comirnaty | Gamaleya - Sputnik-Light |
| Jamaica | Janssen - Ad26.COV 2-S |
| AstraZeneca - Vaxzevria | Pfizer BioNTech - Comirnaty |
| Beijing CNBG - BBIBP-CorV | SII - Covishield |
| Janssen - Ad26.COV 2-S | Sinovac - CoronaVac |
| Pfizer BioNTech - Comirnaty | Latvia |
| SII - Covishield | AstraZeneca - Vaxzevria |
| Japan | Janssen - Ad26.COV 2-S |
| AstraZeneca - Vaxzevria | Moderna - Spikevax |
| Moderna - Spikevax | Novavax-NUVAXOVID |
| Novavax-NUVAXOVID | Pfizer BioNTech - Comirnaty |
| Pfizer BioNTech - Comirnaty | Lebanon |
| Jersey | AstraZeneca - Vaxzevria |
| Moderna - mRNA-1273 | Beijing CNBG - BBIBP-CorV |
| AstraZeneca - AZD1222 | Bharat - Covaxin |
| Pfizer BioNTech - Comirnaty | CanSino - Convidecia |
| Jordan | Gamaleya - Gam-COVID-Vac |
| AstraZeneca - Vaxzevria | Gamaleya - Sputnik-Light |
| Beijing CNBG - BBIBP-CorV | Janssen - Ad26.COV 2-S |
| Bharat - Covaxin | Moderna - Spikevax |
| CanSino - Convidecia | Pfizer BioNTech - Comirnaty |

| COVID-19 Vaccine Types | COVID-19 Vaccine Types |
|-----------------------------|--------------------------------------|
| Sinovac - CoronaVac | Janssen - Ad26.COV 2-S |
| Lesotho | Moderna - Spikevax |
| Beijing CNBG - BBIBP-CorV | Pfizer BioNTech - Comirnaty |
| Janssen - Ad26.COV 2-S | Martinique |
| SII - Covishield | Pfizer BioNTech - Comirnaty |
| Liberia | Mauritania |
| SII - Covishield | Beijing CNBG - BBIBP-CorV |
| Libya | SII - Covishield |
| AstraZeneca - Vaxzevria | Mauritius |
| Beijing CNBG - BBIBP-CorV | Beijing CNBG - BBIBP-CorV |
| Bharat - Covaxin | Bharat - Covaxin |
| CanSino - Convidecia | SII - Covishield |
| Gamaleya - Gam-COVID-Vac | Mexico |
| Gamaleya - Sputnik-Light | AstraZeneca - Vaxzevria |
| Janssen - Ad26.COV 2-S | CanSino - Convidecia |
| Moderna - Spikevax | Gamaleya - Gam-COVID-Vac |
| Pfizer BioNTech - Comirnaty | Janssen - Ad26.COV 2-S |
| Sinovac - CoronaVac | Moderna - Spikevax |
| Liechtenstein | Pfizer BioNTech - Comirnaty |
| Janssen - Ad26.COV 2-S | Sinovac - CoronaVac |
| Moderna - Spikevax | Micronesia (the Federated States of) |
| Pfizer BioNTech - Comirnaty | AstraZeneca - Vaxzevria |
| Lithuania | Janssen - Ad26.COV 2-S |
| AstraZeneca - Vaxzevria | Moderna - Spikevax |
| Janssen - Ad26.COV 2-S | Pfizer BioNTech - Comirnaty |
| Moderna - Spikevax | Monaco |
| Pfizer BioNTech - Comirnaty | AstraZeneca - Vaxzevria |
| Unknown Vaccine | Janssen - Ad26.COV 2-S |
| Luxembourg | Moderna - Spikevax |
| AstraZeneca - Vaxzevria | Novavax - Covavax |
| Janssen - Ad26.COV 2-S | Novavax-NUVAXOVID |
| Moderna - Spikevax | Pfizer BioNTech - Comirnaty |
| Novavax-NUVAXOVID | Mongolia |
| Pfizer BioNTech - Comirnaty | AstraZeneca - Vaxzevria |
| Madagascar | Beijing CNBG - BBIBP-CorV |
| Beijing CNBG - BBIBP-CorV | Gamaleya - Gam-COVID-Vac |
| Janssen - Ad26.COV 2-S | Moderna - Spikevax |
| SII - Covishield | Pfizer BioNTech - Comirnaty |
| Malawi | SII - Covishield |
| Janssen - Ad26.COV 2-S | Montenegro |
| SII - Covishield | AstraZeneca - Vaxzevria |
| Malaysia | Beijing CNBG - BBIBP-CorV |
| AstraZeneca - Vaxzevria | Gamaleya - Gam-COVID-Vac |
| Beijing CNBG - BBIBP-CorV | Pfizer BioNTech - Comirnaty |
| CanSino - Convidecia | Unknown Vaccine |
| Gamaleya - Gam-COVID-Vac | Montserrat |
| Janssen - Ad26.COV 2-S | AstraZeneca - Vaxzevria |
| Moderna - Spikevax | Morocco |
| Pfizer BioNTech - Comirnaty | AstraZeneca - Vaxzevria |
| Sinovac - CoronaVac | Beijing CNBG - BBIBP-CorV |
| Maldives | Bharat - Covaxin |
| AstraZeneca - Vaxzevria | CanSino - Convidecia |
| Beijing CNBG - BBIBP-CorV | Gamaleya - Gam-COVID-Vac |
| Gamaleya - Gam-COVID-Vac | Gamaleya - Sputnik-Light |
| Janssen - Ad26.COV 2-S | Janssen - Ad26.COV 2-S |
| Moderna - Spikevax | Moderna - Spikevax |
| Pfizer BioNTech - Comirnaty | Pfizer BioNTech - Comirnaty |
| SII - Covishield | Sinovac - CoronaVac |
| Sinovac - CoronaVac | Mozambique |
| Mali | Beijing CNBG - BBIBP-CorV |
| SII - Covishield | Janssen - Ad26.COV 2-S |
| Malta | SII - Covishield |
| AstraZeneca - Vaxzevria | Myanmar |
| Janssen - Ad26.COV 2-S | Beijing CNBG - BBIBP-CorV |
| Moderna - Spikevax | SII - Covishield |
| Pfizer BioNTech - Comirnaty | Namibia |
| Marshall Islands | Beijing CNBG - BBIBP-CorV |

| COVID-19 Vaccine Types | COVID-19 Vaccine Types |
|--|-----------------------------|
| Janssen - Ad26.COV 2-S | CanSino - Convidecia |
| Pfizer BioNTech - Comirnaty | Gamaleya - Gam-COVID-Vac |
| SII - Covishield | Gamaleya - Sputnik-Light |
| Nauru | Janssen - Ad26.COV 2-S |
| AstraZeneca - Vaxzevria | Moderna - Spikevax |
| SII - Covishield | Pfizer BioNTech - Comirnaty |
| Nepal | Sinovac - CoronaVac |
| AstraZeneca - Vaxzevria | Oman |
| Beijing CNBG - BBIBP-CorV | AstraZeneca - Vaxzevria |
| Bharat - Covaxin | Beijing CNBG - BBIBP-CorV |
| Gamaleya - Gam-COVID-Vac | Bharat - Covaxin |
| Janssen - Ad26.COV 2-S | CanSino - Convidecia |
| Moderna - Spikevax | Gamaleya - Gam-COVID-Vac |
| Pfizer BioNTech - Comirnaty | Gamaleya - Sputnik-Light |
| SII - Covishield | Janssen - Ad26.COV 2-S |
| Netherlands | Moderna - Spikevax |
| AstraZeneca - Vaxzevria | Pfizer BioNTech - Comirnaty |
| Janssen - Ad26.COV 2-S | SII - Covishield |
| Moderna - Spikevax | Sinovac - CoronaVac |
| Novavax-NUVAXOVID | Pakistan |
| Pfizer BioNTech - Comirnaty | AstraZeneca - Vaxzevria |
| Unknown Vaccine | Beijing CNBG - BBIBP-CorV |
| New Caledonia | Bharat - Covaxin |
| Janssen - Ad26.COV 2-S | CanSino - Convidecia |
| Pfizer BioNTech - Comirnaty | Gamaleya - Gam-COVID-Vac |
| New Zealand | Gamaleya - Sputnik-Light |
| AstraZeneca - Vaxzevria | Janssen - Ad26.COV 2-S |
| Janssen - Ad26.COV 2-S | Moderna - Spikevax |
| Novavax-NUVAXOVID | Pfizer BioNTech - Comirnaty |
| Pfizer BioNTech - Comirnaty | SII - Covishield |
| Nicaragua | Sinovac - CoronaVac |
| AstraZeneca - Vaxzevria | Palau |
| CIGB - CIGB-66 | Janssen - Ad26.COV 2-S |
| Finlay - Soberana Plus | Moderna - Spikevax |
| Finlay - Soberana-02 | Pfizer BioNTech - Comirnaty |
| Gamaleya - Gam-COVID-Vac | Panama |
| Gamaleya - Sputnik-Light | AstraZeneca - Vaxzevria |
| Janssen - Ad26.COV 2-S | Pfizer BioNTech - Comirnaty |
| Pfizer BioNTech - Comirnaty | Papua New Guinea |
| SII - Covishield | AstraZeneca - Vaxzevria |
| Niger | Beijing CNBG - BBIBP-CorV |
| Beijing CNBG - BBIBP-CorV | Janssen - Ad26.COV 2-S |
| SII - Covishield | SII - Covishield |
| Nigeria | Paraguay |
| SII - Covishield | AstraZeneca - Vaxzevria |
| Niue | Beijing CNBG - BBIBP-CorV |
| Pfizer BioNTech - Comirnaty | Bharat - Covaxin |
| North Macedonia | Gamaleya - Gam-COVID-Vac |
| AstraZeneca - Vaxzevria | Julphar - Hayat-Vax |
| Beijing CNBG - BBIBP-CorV | Moderna - Spikevax |
| Gamaleya - Gam-COVID-Vac | Pfizer BioNTech - Comirnaty |
| Pfizer BioNTech - Comirnaty | Sinovac - CoronaVac |
| Sinovac - CoronaVac | Peru |
| Wuhan CNBG - Inactivated | AstraZeneca - Vaxzevria |
| Northern Mariana Islands (Commonwealth of the) | Beijing CNBG - BBIBP-CorV |
| Janssen - Ad26.COV 2-S | Moderna - Spikevax |
| Moderna - Spikevax | Pfizer BioNTech - Comirnaty |
| Pfizer BioNTech - Comirnaty | Philippines |
| Norway | AstraZeneca - Vaxzevria |
| AstraZeneca - Vaxzevria | Beijing CNBG - BBIBP-CorV |
| Janssen - Ad26.COV 2-S | Bharat - Covaxin |
| Moderna - Spikevax | Gamaleya - Gam-COVID-Vac |
| Pfizer BioNTech - Comirnaty | Gamaleya - Sputnik-Light |
| occupied Palestinian territory | Janssen - Ad26.COV 2-S |
| AstraZeneca - Vaxzevria | Julphar - Hayat-Vax |
| Beijing CNBG - BBIBP-CorV | Moderna - Spikevax |
| Bharat - Covaxin | Novavax-NUVAXOVID |

| COVID-19 Vaccine Types | COVID-19 Vaccine Types |
|-----------------------------|----------------------------------|
| Pfizer BioNTech - Comirnaty | AstraZeneca - AZD1222 |
| Sinovac - CoronaVac | Saint Kitts and Nevis |
| Pitcairn Islands | AstraZeneca - Vaxzevria |
| AstraZeneca - Vaxzevria | Pfizer BioNTech - Comirnaty |
| Poland | SII - Covishield |
| AstraZeneca - Vaxzevria | Saint Lucia |
| Janssen - Ad26.COV 2-S | AstraZeneca - Vaxzevria |
| Moderna - Spikevax | Janssen - Ad26.COV 2-S |
| Novavax-NUVAXOVID | Moderna - Spikevax |
| Pfizer BioNTech - Comirnaty | Pfizer BioNTech - Comirnaty |
| Portugal | SII - Covishield |
| AstraZeneca - Vaxzevria | Saint Vincent and the Grenadines |
| Beijing CNBG - BBIBP-CorV | AstraZeneca - Vaxzevria |
| Bharat - Covaxin | Gamaleya - Gam-COVID-Vac |
| Janssen - Ad26.COV 2-S | Gamaleya - Sputnik-Light |
| Moderna - Spikevax | Pfizer BioNTech - Comirnaty |
| Novavax-NUVAXOVID | SII - Covishield |
| Pfizer BioNTech - Comirnaty | Samoa |
| Sinovac - CoronaVac | AstraZeneca - Vaxzevria |
| Puerto Rico | Pfizer BioNTech - Comirnaty |
| Janssen - Ad26.COV 2-S | San Marino |
| Moderna - Spikevax | Gamaleya - Gam-COVID-Vac |
| Pfizer BioNTech - Comirnaty | Pfizer BioNTech - Comirnaty |
| Qatar | Sao Tome and Principe |
| AstraZeneca - Vaxzevria | AstraZeneca - Vaxzevria |
| Beijing CNBG - BBIBP-CorV | SII - Covishield |
| Bharat - Covaxin | Saudi Arabia |
| CanSino - Convidecia | AstraZeneca - Vaxzevria |
| Gamaleya - Gam-COVID-Vac | Beijing CNBG - BBIBP-CorV |
| Gamaleya - Sputnik-Light | Bharat - Covaxin |
| Janssen - Ad26.COV 2-S | CanSino - Convidecia |
| Moderna - Spikevax | Gamaleya - Gam-COVID-Vac |
| Pfizer BioNTech - Comirnaty | Gamaleya - Sputnik-Light |
| Sinovac - CoronaVac | Janssen - Ad26.COV 2-S |
| Republic of Korea | Moderna - Spikevax |
| AstraZeneca - Vaxzevria | Pfizer BioNTech - Comirnaty |
| Janssen - Ad26.COV 2-S | Sinovac - CoronaVac |
| Moderna - Spikevax | Senegal |
| Novavax-NUVAXOVID | Beijing CNBG - BBIBP-CorV |
| Pfizer BioNTech - Comirnaty | Janssen - Ad26.COV 2-S |
| Republic of Moldova | SII - Covishield |
| AstraZeneca - Vaxzevria | Serbia |
| Beijing CNBG - BBIBP-CorV | AstraZeneca - Vaxzevria |
| Gamaleya - Gam-COVID-Vac | Beijing CNBG - BBIBP-CorV |
| Janssen - Ad26.COV 2-S | Gamaleya - Gam-COVID-Vac |
| Moderna - Spikevax | Moderna - Spikevax |
| Pfizer BioNTech - Comirnaty | Pfizer BioNTech - Comirnaty |
| Sinovac - CoronaVac | Seychelles |
| Romania | Beijing CNBG - BBIBP-CorV |
| AstraZeneca - Vaxzevria | Gamaleya - Gam-COVID-Vac |
| Janssen - Ad26.COV 2-S | Julphar - Hayat-Vax |
| Moderna - Spikevax | SII - Covishield |
| Pfizer BioNTech - Comirnaty | Sierra Leone |
| Russian Federation | Beijing CNBG - BBIBP-CorV |
| SRCVB - EpiVacCorona | SII - Covishield |
| Gamaleya - Sputnik V | Singapore |
| Rwanda | AstraZeneca - Vaxzevria |
| Beijing CNBG - BBIBP-CorV | Beijing CNBG - BBIBP-CorV |
| Gamaleya - Gam-COVID-Vac | Moderna - Spikevax |
| Janssen - Ad26.COV 2-S | Pfizer BioNTech - Comirnaty |
| Moderna - Spikevax | Sint Eustatius |
| Pfizer BioNTech - Comirnaty | None |
| SII - Covishield | Sint Maarten |
| Sinovac - CoronaVac | AstraZeneca - Vaxzevria |
| Saba | Moderna - Spikevax |
| None | Pfizer BioNTech - Comirnaty |
| Saint Helena | Slovakia |

| COVID-19 Vaccine Types | COVID-19 Vaccine Types |
|-----------------------------|-----------------------------|
| AstraZeneca - Vaxzevria | Moderna - Spikevax |
| Gamaleya - Gam-COVID-Vac | Novavax-NUVAXOVID |
| Janssen - Ad26.COV 2-S | Pfizer BioNTech - Comirnaty |
| Moderna - Spikevax | Unknown Vaccine |
| Novavax-NUVAXOVID | Switzerland |
| Pfizer BioNTech - Comirnaty | Janssen - Ad26.COV 2-S |
| Slovenia | Moderna - Spikevax |
| AstraZeneca - Vaxzevria | Pfizer BioNTech - Comirnaty |
| Janssen - Ad26.COV 2-S | The Syrian Arab Republic |
| Moderna - Spikevax | AstraZeneca - Vaxzevria |
| Novavax-NUVAXOVID | Beijing CNBG - BBIBP-CorV |
| Pfizer BioNTech - Comirnaty | Bharat - Covaxin |
| Solomon Islands | CanSino - Convidecia |
| AstraZeneca - Vaxzevria | Gamaleya - Gam-COVID-Vac |
| Beijing CNBG - BBIBP-CorV | Gamaleya - Sputnik-Light |
| Pfizer BioNTech - Comirnaty | Janssen - Ad26.COV 2-S |
| SII - Covishield | Moderna - Spikevax |
| Somalia | Pfizer BioNTech - Comirnaty |
| AstraZeneca - Vaxzevria | SII - Covishield |
| Beijing CNBG - BBIBP-CorV | Sinovac - CoronaVac |
| Bharat - Covaxin | Tajikistan |
| CanSino - Convidecia | AstraZeneca - Vaxzevria |
| Gamaleya - Gam-COVID-Vac | Gamaleya - Gam-COVID-Vac |
| Gamaleya - Sputnik-Light | Moderna - Spikevax |
| Janssen - Ad26.COV 2-S | Pfizer BioNTech - Comirnaty |
| Moderna - Spikevax | SII - Covishield |
| Pfizer BioNTech - Comirnaty | Sinovac - CoronaVac |
| SII - Covishield | Thailand |
| Sinovac - CoronaVac | AstraZeneca - Vaxzevria |
| South Africa | Beijing CNBG - BBIBP-CorV |
| Janssen - Ad26.COV 2-S | Janssen - Ad26.COV 2-S |
| Pfizer BioNTech - Comirnaty | Moderna - Spikevax |
| South Sudan | Pfizer BioNTech - Comirnaty |
| Janssen - Ad26.COV 2-S | SII - Covishield |
| SII - Covishield | SII - Covovax |
| Spain | Sinovac - CoronaVac |
| AstraZeneca - Vaxzevria | The United Kingdom |
| Janssen - Ad26.COV 2-S | AstraZeneca - Vaxzevria |
| Moderna - Spikevax | Moderna - Spikevax |
| Pfizer BioNTech - Comirnaty | Pfizer BioNTech - Comirnaty |
| Sri Lanka | Timor-Leste |
| AstraZeneca - Vaxzevria | AstraZeneca - Vaxzevria |
| Beijing CNBG - BBIBP-CorV | Pfizer BioNTech - Comirnaty |
| Gamaleya - Gam-COVID-Vac | SII - Covishield |
| Moderna - Spikevax | Sinovac - CoronaVac |
| Pfizer BioNTech - Comirnaty | Togo |
| SII - Covishield | SII - Covishield |
| Sudan | Tokelau |
| AstraZeneca - Vaxzevria | Pfizer BioNTech - Comirnaty |
| Beijing CNBG - BBIBP-CorV | Tonga |
| Bharat - Covaxin | AstraZeneca - Vaxzevria |
| CanSino - Convidecia | Pfizer BioNTech - Comirnaty |
| Gamaleya - Gam-COVID-Vac | Trinidad and Tobago |
| Gamaleya - Sputnik-Light | AstraZeneca - Vaxzevria |
| Janssen - Ad26.COV 2-S | Beijing CNBG - BBIBP-CorV |
| Moderna - Spikevax | Janssen - Ad26.COV 2-S |
| Pfizer BioNTech - Comirnaty | Pfizer BioNTech - Comirnaty |
| SII - Covishield | SII - Covishield |
| Sinovac - CoronaVac | Tunisia |
| Suriname | AstraZeneca - Vaxzevria |
| AstraZeneca - Vaxzevria | Beijing CNBG - BBIBP-CorV |
| Beijing CNBG - BBIBP-CorV | Bharat - Covaxin |
| Moderna - Spikevax | CanSino - Convidecia |
| Pfizer BioNTech - Comirnaty | Gamaleya - Gam-COVID-Vac |
| SII - Covishield | Gamaleya - Sputnik-Light |
| Sweden | Janssen - Ad26.COV 2-S |
| AstraZeneca - Vaxzevria | Moderna - Spikevax |

| COVID-19 Vaccine Types | COVID-19 Vaccine Types |
|-----------------------------|-------------------------------------|
| Pfizer BioNTech - Comirnaty | Janssen - Ad26.COV 2-S |
| Sinovac - CoronaVac | Venezuela (the Bolivarian Republic) |
| Turkey | Beijing CNBG - BBIBP-CorV |
| Pfizer BioNTech - Comirnaty | CIGB - CIGB-66 |
| Sinovac - CoronaVac | Finlay - Soberana-02 |
| Turkovac | Gamaleya - Gam-COVID-Vac |
| Turkmenistan | Gamaleya - Sputnik-Light |
| Anhui ZL - Zifivax | Sinovac - CoronaVac |
| AstraZeneca - Vaxzevria | Viet Nam |
| Beijing CNBG - BBIBP-CorV | AstraZeneca - Vaxzevria |
| Gamaleya - Gam-COVID-Vac | Beijing CNBG - BBIBP-CorV |
| RIBSP - QazVac | CIGB - CIGB-66 |
| SRCVB - EpiVacCorona | Gamaleya - Gam-COVID-Vac |
| Unknown Vaccine | Moderna - Spikevax |
| Turks and Caicos Islands | Pfizer BioNTech - Comirnaty |
| Pfizer BioNTech - Comirnaty | Wallis and Futuna |
| Tuvalu | Moderna - Spikevax |
| AstraZeneca - AZD1222 | Yemen |
| Uganda | AstraZeneca - Vaxzevria |
| Janssen - Ad26.COV 2-S | Beijing CNBG - BBIBP-CorV |
| Moderna - Spikevax | Bharat - Covaxin |
| Pfizer BioNTech - Comirnaty | CanSino - Convidecia |
| SII - Covishield | Gamaleya - Gam-COVID-Vac |
| Sinovac - CoronaVac | Gamaleya - Sputnik-Light |
| Ukraine | Janssen - Ad26.COV 2-S |
| AstraZeneca - Vaxzevria | Moderna - Spikevax |
| Janssen - Ad26.COV 2-S | Pfizer BioNTech - Comirnaty |
| Moderna - Spikevax | SII - Covishield |
| Pfizer BioNTech - Comirnaty | Sinovac - CoronaVac |
| SII - Covishield | Zambia |
| Sinovac - CoronaVac | Beijing CNBG - BBIBP-CorV |
| United Arab Emirates | Janssen - Ad26.COV 2-S |
| AstraZeneca - Vaxzevria | SII - Covishield |
| Beijing CNBG - BBIBP-CorV | Zimbabwe |
| Bharat - Covaxin | Beijing CNBG - BBIBP-CorV |
| CanSino - Convidecia | Bharat - Covaxin |
| Gamaleya - Gam-COVID-Vac | Gamaleya - Gam-COVID-Vac |
| Gamaleya - Sputnik-Light | Sinovac - CoronaVac |
| Janssen - Ad26.COV 2-S | Grand Total |
| Moderna - Spikevax | |
| Pfizer BioNTech - Comirnaty | |
| SII - Covishield | |
| Sinovac - CoronaVac | |
| United Republic of Tanzania | |
| Beijing CNBG - BBIBP-CorV | |
| Janssen - Ad26.COV 2-S | |
| Pfizer BioNTech - Comirnaty | |
| United States of America | |
| Janssen - Ad26.COV 2-S | |
| Moderna - Spikevax | |
| Pfizer BioNTech - Comirnaty | |
| Uruguay | |
| AstraZeneca - Vaxzevria | |
| Pfizer BioNTech - Comirnaty | |
| Sinovac - CoronaVac | |
| Uzbekistan | |
| Anhui ZL - Zifivax | |
| Gamaleya - Gam-COVID-Vac | |
| Gamaleya - Sputnik-Light | |
| Moderna - Spikevax | |
| Pfizer BioNTech - Comirnaty | |
| SII - Covishield | |
| Sinovac - CoronaVac | |
| Unknown Vaccine | |
| Vanuatu | |
| AstraZeneca - Vaxzevria | |
| Beijing CNBG - BBIBP-CorV | |

References

- [1] V. Ramamurthy et al., The Life-Saving Mission for COVID-19 Vaccination on Google Cloud (GC) Ecosystem, International Journal of Science and Research (IJSR), ISSN: 2319-7064, SJIF (2022): 7.94, pages 1365-1365.
- [2] Han X, Xu P, Ye Q. Analysis of COVID-19 vaccines: Types, thoughts, and application. J Clin Lab Anal. 2021 Sep; 35 (9): e23937. DOI: 10.1002/jcla.23937. Epub 2021 Aug 15. PMID: 34396586; PMCID: PMC8418485.
- [3] He Q, Mao Q, Zhang J, Bian L, Gao F, Wang J, Xu M, Liang Z. COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations. Front Immunol. 2021 Apr 12; 12: 669339. DOI: 10.3389/fimmu.2021.669339. PMID: 33912196; PMCID: PMC8071852.
- [4] Centers for Disease Control and Prevention. (2020). CDC Methods for the Establishment and Management of Public Health Rapid Response Teams for Disease Outbreaks. Atlanta: Centers for Disease Control and Prevention. <https://www.cdc.gov/globalhealth/healthprotection/errb/pdf/RTManagementGuidance-508.pdf>pdf icon

- [5] Wibawa T. COVID-19 vaccine research and development: ethical issues. *Trop Med Int Health*. 2021 Jan; 26 (1): 14-19. DOI: 10.1111/tmi.13503. Epub 2020 Oct 19. PMID: 33012020; PMCID: PMC7675299.
- [6] Hellewell, J., Abbott, S., Gimma, A., Bosse, N., Jarvis, C., & Russell, T. et al. (2020). Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. *The Lancet*, 8 (4), 488-496. [https://doi.org/10.1016/S2214-109X\(20\)30074-7](https://doi.org/10.1016/S2214-109X(20)30074-7)external icon
- [7] Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report. *Immunity*. 2020 Apr 14; 52 (4): 583-589. doi: 10.1016/j.immuni.2020.03.007. Epub 2020 Apr 6. PMID: 32259480; PMCID: PMC7136867.
- [8] World Health Organization. (2020). COVID-19 Strategy Update. Geneva: WHO. Retrieved 11 May 2020, from <https://www.who.int/publications-detail/COVID-19-strategy-update—14-April-2020>external icon
- [9] World Health Organization. (2020). COVID-19: Operational Planning Guidelines and COVID-19 Partners Platform to support country preparedness and response. Retrieved 28 April 2020, from <https://openwho.org/courses/UNCT-COVID-19-preparedness-and-response-EN>external icon.
- [10] Centers for Disease Control and Prevention. (2020). COVID-19 72-hour Response Plan Checklist. Atlanta: CDC. <https://www.cdc.gov/coronavirus/2019-ncov/global-COVID-19/index.html>
- [11] Chuang, Isaac and Ho, Andrew, HarvardX and MITx: Four Years of Open Online Courses -- Fall 2012-Summer 2016 (December 23, 2016). Available at SSRN: <https://ssrn.com/abstract=2889436> or <http://dx.doi.org/10.2139/ssrn.2889436>
- [12] Lopez, G., Seaton, D. T., Ang, A. M., Tingley, D., & Chuang, I. L. (2017). Google BigQuery for Education: Framework for Parsing and Analyzing edX MOOC Data. *Proceedings of the Fourth (2017) ACM Conference on Learning @ Scale*. Davidson College. 2015. A Liberal Arts Take on Tech. <https://www.davidson.edu/news/news-stories/>
- [13] Costello, E., Corcoran, M., Barnett, J. S., Birkmeier, M., Cohn, R., Ekmekci, O. ... Walker, B. (2014). Information and communication technology to facilitate learning for students in the health professions: Current uses, gaps, and future directions. *Online Learning: Official Journal of the Online Learning Consortium*, 18 (4). Retrieved from <http://olj.onlinelearningconsortium.org/index.php/jaln/article/view/512/118> edX Documentation. 2016. Research Guide. (2016). <http://edx.readthedocs.io/projects/devdata/en/latest/>.
- [14] Harvard Vice Provost for Advances in Learning Research. 2016. Harvard VPAL Private Datasets Documentation. (2016). <http://dx.doi.org/10.7910/DVN/RTVIEM>.
- [15] Harvard Gazette. 2016. MOOCS Ahead. (2016). <http://news.harvard.edu/gazette/story/2016/07/moocs-ahead/>.Google. 2016. Google App Engine. (25 October 2016). <https://cloud.google.com/appengine/docs>.
- [16] Harvard and MIT. 2016a. edx2bigquery. (25 October 2016). <https://github.com/mitodl/edx2bigquery>.
- [17] Harvard and MIT. 2016b. analytics. (25 October 2016). <https://github.com/mitodl/xanalytics>.
- [18] Andrew Dean Ho, Isaac Chuang, Justin Reich, Cody Austin Coleman, Jacob Whitehill, Curtis G. Northcutt, Joseph Jay Williams, John D Hansen, Glenn Lopez, and Rebecca Petersen. 2015. Harvard and MITx: Two years of Open Online Courses, Fall 2012 - Summer 2014. Available at SSRN 2586847 (2015).
- [19] Andrew Dean Ho, Justin Reich, Sergiy O Nesterko, Daniel Thomas Seaton, Tommy Mullaney, Jim Waldo, and Isaac Chuang. 2014. HarvardX and MITx: The First Year of Open Online Courses, Fall 2012 - Summer 2013. Available at SSRN 2381263 (2014).
- [20] Maxmind. 2016. GeoIP2 City Database. (2016). <https://www.maxmind.com/en/geoip2-city>.
- [21] Kalyan Veeramachaneni, Franck Dernoncourt, Colin Taylor, Zachary Pardos, and Una-May O'Reilly. 2013.
- [22] Moocdb: Developing data standards for MOOC data science. In *AIED 2013 Workshops Proceedings Volume*. Citeseer, 17.
- [23] Elise Young. 2015. Educational privacy in the online classroom: FERPA, MOOCs, and the big data problem. *Harv. J. Law & Tec* 28 (2015), 549-593. John Zornig. 2016. MOOCczar. (25 October 2016). <https://github.com/UQ-UQx/MOOCczar>
- [24] Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. *J Virol*. 2020 Mar 17; 94 (7): e00127-20. DOI: 10.1128/JVI.00127-20. PMID: 31996437; PMCID: PMC7081895.
- [25] World Health Organization. (2020). Coronavirus disease (COVID-19) outbreak: health workers' rights, roles, and responsibilities, including key considerations for occupational safety and health. Geneva: WHO. Retrieved 11 May 2020, from [https://www.who.int/publications-detail/coronavirus-disease-\(COVID-19\)-outbreak-rights-roles-and-responsibilities-of-health-workers-including-key-considerations-for-occupational-safety-and-health](https://www.who.int/publications-detail/coronavirus-disease-(COVID-19)-outbreak-rights-roles-and-responsibilities-of-health-workers-including-key-considerations-for-occupational-safety-and-health) external icon
- [26] Pfeiffer, Paul N, Blow, Adrian J, Ph.D.; Miller, Erin, MS; Forman, Jane, ScD; Dalack, Gregory W, MD; et al. (2012), Peers and Peer-Based Interventions in Supporting Reintegration and Mental Health Among National Guard Soldiers: A Qualitative Study. *Military Medicine*; 177, 12: 1471.
- [27] Greden, J. F., Valenstein, M., Spinner, J., Blow, A., Gorman, L. A., Dalack, G. W., Marcus, S., and Kees, M. (2010), Buddy-to-Buddy, a citizen soldier peer support program to counteract stigma, PTSD, depression, and suicide. *Annals of the New York Academy of Sciences*, 1208: 90-97. DOI: 10.1111/j.1749-6632.2010.05719.
- [28] Finnegan, A., Lauder, W., & McKenna, H. (2016). The challenges and psychological impact of delivering nursing care within a war zone. *Nursing Outlook*, 64 (5), 450-458.
- [29] World Health Organization. (2020). Course: RRT Training Packages for COVID-19. Retrieved 28 April 2020, from <https://extranet.who.int/hslp/training/course/view.php?id=327> external icon.
- [30] World Health Organization. (2020). Health Security Learning Platform. Retrieved 28 April 2020, from <https://extranet.who.int/hslp/training/external> icon.

- [31] Chen, J. (2020). Pathogenicity and transmissibility of 2019-nCoV—A quick overview and comparison with other emerging viruses. *Microbes and Infection*, 22 (2), 69-71. <https://doi.org/10.1016/j.micinf.2020.01.004>external icon
- [32] World Health Organization. (2020). Considerations in the investigation of cases and clusters of COVID-19. Geneva: WHO. Retrieved 12 May 2020, from <https://www.who.int/publications-detail/considerations-in-the-investigation-of-cases-and-clusters-of-COVID-19>external icon
- [33] World Health Organization. (2020). Laboratory testing for COVID-19 in suspect human cases. Geneva: WHO. Retrieved 12 May 2020, from <https://apps.who.int/iris/handle/10665/331329>external icon
- [34] Centers for Disease Control and Prevention. (2020). Strategic Priority Infection Prevention and Control Activities for Non-US Healthcare Settings. Atlanta: CDC. Retrieved 12 May 2020, from <https://www.cdc.gov/coronavirus/2019-ncov/hcp/non-us-settings/index.html>
- [35] World Health Organization. (2020). Infection prevention and control during health care when COVID-19 is suspected. Geneva: WHO. Retrieved 12 May 2020, from [https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-\(ncov\)-infection-is-suspected-20200125](https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125)external icon
- [36] World Health Organization. (2020). Operational considerations for case management of COVID-19 in health facilities and community. Geneva: WHO. Retrieved 12 May 2020, from <https://www.who.int/publications-detail/operational-considerations-for-case-management-of-COVID-19-in-health-facility-and-community>external icon
- [37] World Health Organization. (2020). Risk communication and community engagement readiness and response to COVID-19. Geneva: WHO. Retrieved 12 May 2020, from [https://www.who.int/publications-detail/risk-communication-and-community-engagement-readiness-and-initial-response-for-novel-coronaviruses-\(ncov\)](https://www.who.int/publications-detail/risk-communication-and-community-engagement-readiness-and-initial-response-for-novel-coronaviruses-(ncov))external icon
- [38] World Health Organization. (2020). Risk assessment and management of exposure of health care workers in the context of COVID-19: interim guidance, 19 March 2020. Geneva: WHO. Retrieved 11 May 2020, from <https://apps.who.int/iris/handle/10665/331496>external icon
- [39] Krishnan S. P. T. Krishnan S. P. T. Jose L. Ugia Gonzalez, Getting Started with Google Cloud Platform, January 2015, DOI: 10.1007/978-1-4842-1004-8_2.
- [40] Krishnan S. P. T. Jose L. Ugia Gonzalez, Google App Engine, January 2015, DOI: 10.1007/978-1-4842-1004-8_5.